智通财经网·2025-12-02 12:57Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical, has received acceptance for its drug registration application for Heparin Sodium Injection from the National Medical Products Administration of China, indicating progress in the commercialization of this self-developed chemical drug [1] Company Summary - The Heparin Sodium Injection is intended for multiple medical uses, including the prevention and treatment of venous thrombosis, pulmonary embolism, and anticoagulation during surgeries and dialysis [1] - As of October 2025, the cumulative R&D investment for this drug by Suzhou Er Ye is approximately RMB 8.61 million (unaudited) [1] - The projected sales revenue for Heparin Sodium Injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is estimated to be around RMB 1.386 billion in 2024 according to IQVIA CHPA data [1] - The acceptance of the drug registration application is not expected to have a significant impact on the company's current performance [1]